Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Glaucoma agents effective in reducing diurnal, trough IOPs
Charleston, SC-When prescribing brimonidine 0.2% b.i.d. as monotherapy for ocular hypertension or primary open-angle glaucoma, physicians should make sure that the drug maintains its effectiveness in the late afternoon and may want to add a third drop to the daily dosage, said William C. Stewart, MD.
Related Videos
Related Content
